MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of the American Academy of Dermatology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,255 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,255 works in the cohort · of 4,299,418page 22 of 26

Labels cover 0 of 1,255 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,255 of 1,255 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Response to: “Response to Bissonnette et al. Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy control–matched, phase 4 clinical study (BALISTAD)”
Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, Donald Y.M. Leung
2025· letter· en· Journal of the American Academy of Dermatology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Ciclopirox shampoo: an overview
Aditya K. Gupta
2004· article· en· Journal of the American Academy of Dermatology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
54390 A Systematic Review on Treatment Outcomes of Striae
Catherine Zhu, Lorena Alexandra Mija, Kaouthar Koulmi, Ilya Mukovozov
2024· review· en· Journal of the American Academy of Dermatology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, Meghan Feely, Danting Zhu +5 more
2023· article· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
fundno affno abstractunlabeled
Implementation of Mohs micrographic surgery at the VA New York Manhattan Harbor Healthcare System eliminated need for re-excision and decreased time to treatment: A retrospective and prospective cohort study
Jaclyn Rosenthal Himeles, Alexa B. Steuer, Daniel Gutiérrez, John G. Zampella, Mary L. Stevenson, John A. Carucci +1 more
2023· article· en· Journal of the American Academy of Dermatology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
51582 Simultaneous Genital Skin Clearance and Patient Reported Outcome Responses at Weeks 24 and 52 in Patients with Moderate-to-Severe Genital Psoriasis Treated with Ixekizumab: an analysis of the Phase 3 Clinical Trial IXORA-Q
Jennifer Clay Cather, Jennifer Soung, Gil Yosipovitch, Caitriona Ryan, Mohamed El Rayes, Bruce W. Konicek +4 more
2024· article· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial
Mark Lebwohl, Michael Bukhalo, Linda Stein‐Gold, Michelle T. Pelle, Bradley Glick, Maria Llamas-Velasco +5 more
2024· article· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About